# Pizarra — PT-pseudo_175e6ad47991 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_175e6ad47991
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 79-year-old male
  - PSA: 28.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.28 ng/mL²
  - PSA velocity: 2.75 ng/mL/yr
  - Prior PSA: 16.6 ng/mL
  - Prostate volume: 100.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.3807473 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 28 ng/mL. PI-RADS 5. PSAD 0.28. Prostate volume 100 mL. csPCa 0.38.

Vitals: weight 88 kg, height 183 cm, BMI 26.3, BP 130/64 mmHg, HR 84 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2002).

Chief complaint: Evaluation of a marked serum prostate-specific antigen increase to 28.0 ng/mL alongside reassessment of previously negative biopsy results.

History: Residing in a ground-floor apartment with his wife, the seventy-nine-year-old retired warehouse worker first came to attention regarding a prostate-specific antigen elevation documented in mid-2022. He maintains a steady lifestyle featuring weekly swimming sessions and moderate alcohol intake averaging 20 units weekly. Mild lower urinary tract symptoms are present, corresponding to an IPSS score of 9, though acute urinary retention and haematuria are absent. Past medical history remains clear save for an appendectomy performed in his youth and a recent routine cognitive screening at a memory clinic. Ex-smoker (30 pack-yr, quit 2002). Participation in any prostate cancer research trials was previously declined. Comorbidities are absent, and he takes no active medications.

Physical examination: DRE: Normal. Prostate is symmetrically enlarged with smooth, firm consistency and no palpable asymmetry or discrete nodules. General examination remains within normal limits, featuring stable vitals and absent lymphadenopathy or bone tenderness. Abdominal palpation is soft and non-tender, with a palpable bladder correlating with the documented prostate volume.

Patient info: retired warehouse worker; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 20 units / week; exercise Swimming 1x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Audiology — hearing test; Memory clinic — baseline screening.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.71 +/- 0.19   (95% CI 0.34-1.00)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.19  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.87 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence that changes the clinical picture regarding biopsy necessity?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on the mpMRI findings and the history of prior negative biopsy, as the statistical prior and protocol criterion are inconclusive without the detailed reports.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed structured panel data (PSA 28.0, PI-RADS 5, PSA density 0.28, etc.) and could not account for the clinical context, such as the patient's history of moderate LUTS (IPSS 9/35) or his prior negative biopsy status.
The prior cannot weigh the clinical significance of the prior negative biopsy result against the high PI-RADS 5 score, which is a key conflict point.
The prior does not incorporate the specific guideline criterion that dictates the management pathway for a prior negative biopsy in this context.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests BIOPSY with a high probability (0.71), but the epistemic uncertainty (dp = 0.19) is large, suggesting the model is highly uncertain about this specific patient profile.
The protocol criterion suggests BIOPSY based on the PI-RADS 5, but the prior positive prediction might be wrong if the high PI-RADS score is misleading or if the prior negative biopsy is highly predictive of a benign outcome in this specific patient.
The model might be wrong because it failed to weigh the conflict between the high PI-RADS score and the prior negative biopsy result against the specific guideline track record.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
laboratory panel - What are the full laboratory results, specifically looking for PSA trend data beyond the headline value?
previous_notes - What is the specific clinical context regarding the prior negative biopsy result?
GUIDELINE ANCHOR - The guideline constrains the decision by stating that re-biopsy is indicated when the mpMRI shows a PI-RADS 4-5 lesion, and does not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion in the right posterior peripheral zone (base-to-mid), approximately 25 mm. Lesion size is 25 mm. No evidence of capsular breach, seminal vesicle invasion, nodal enlargement, or osseous metastasis.
get_psa_trend
PSA trend: Shows a rising trajectory: 2.5 ng/mL (Jun 2022) to 28.0 ng/mL (Jan 2025).
get_previous_notes
Previous notes: Prior biopsy was "Negative". The last documented PSA was 16.6 ng/mL on 08 May 2024. Coordination for a urology visit was initiated following the review of the trend and the prior negative biopsy.

NOT RETRIEVED
get_lab_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no information from the retrieved documents raised a specific question requiring its retrieval.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right posterior peripheral zone (base-to-mid), approximately 25 mm.
- PSA trend: Rising trajectory from 16.6 ng/mL to 28.0 ng/mL.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy result was "Negative".

WHERE THIS LEANS
The evidence strongly supports re-biopsy based on the PI-RADS 5 finding and the rising PSA trend, aligning with the EXPERT-PROTOCOL criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report showing PI-RADS 5 and rising PSA trend, and previous notes confirming a negative biopsy) provide sufficient information to align with the EXPERT-PROTOCOL criterion, leading to a clear recommendation for biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is supported by convergence across the statistical prior, the guideline criterion, and the retrieved evidence. The PI-RADS 5 finding on the mpMRI is decisive, aligning with the protocol criterion for re-biopsy when a high-risk lesion is identified. This finding was further supported by the rising PSA trend from 16.6 ng/mL to 28.0 ng/mL, which provided the necessary clinical context to overturn the prior negative biopsy status.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
